{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 55,
  "pageCount": 56,
  "prevPage": 54,
  "nextPage": 56,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a biological pathway diagram to illustrate the mechanism of action.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/55",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.45,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Biological pathway diagram showing EGFR, SHP2, RAS, and downstream signaling",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8de7417-c084-4b20-841e-1e915d8c4990",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "list",
      "text": "EGFR-driven CRC and HPV-negative HNSCC are highly dependent on RAS/MAPK pathway signaling. Dual blockade of EGFR and SHP2 could potentially broaden and deepen responses compared to EGFR inhibition alone, including in: Triple wildtype CRC (nearly 50% of patients); HPV-negative HNSCC (70-75% of patients).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5df82c38-850b-415f-87ba-e9a96e7c82ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.95,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Scientific rationale: Dual inhibition of EGFR and SHP2 in triple wildtype CRC and HPV-negative head and neck squamous cell carcinoma (HNSCC)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee243678-13fe-4f19-afa4-6dc3e01eeb0d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "aad7b468-f2e0-458d-a03d-46eb3d769275",
      "evidence": "The diagram illustrates the causal signaling pathway from EGFR/SHP2 to downstream cellular effects.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}